Patritumab deruxtecan's BLA withdrawal was due to HERTHENA-Lung02 trial's unsatisfactory overall survival results, despite progression-free survival significance. The HERTHENA-Lung02 trial compared ...
AbbVie Submits BLA To FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer
(RTTNews) - AbbVie (ABBV) announced submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for accelerated approval of telisotuzumab vedotin (Teliso-V) in adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results